Penn Capital Management Company LLC Buys New Shares in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Penn Capital Management Company LLC purchased a new position in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 131,794 shares of the medical equipment provider's stock, valued at approximately $11,790,000. Penn Capital Management Company LLC owned about 0.19% of Lantheus as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Wilmington Savings Fund Society FSB purchased a new stake in shares of Lantheus during the third quarter worth approximately $25,000. Kestra Investment Management LLC acquired a new stake in Lantheus in the 4th quarter valued at about $27,000. Summit Securities Group LLC acquired a new position in shares of Lantheus during the 4th quarter worth approximately $37,000. UMB Bank n.a. increased its holdings in shares of Lantheus by 31.5% in the fourth quarter. UMB Bank n.a. now owns 559 shares of the medical equipment provider's stock valued at $50,000 after purchasing an additional 134 shares during the last quarter. Finally, World Investment Advisors LLC acquired a new position in shares of Lantheus during the 3rd quarter valued at about $60,000. 99.06% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other news, Director Mary Anne Heino sold 53,107 shares of the stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $94.35, for a total value of $5,010,645.45. Following the sale, the director now directly owns 440,399 shares in the company, valued at $41,551,645.65. This represents a 10.76 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Robert J. Jr. Marshall sold 10,000 shares of the company's stock in a transaction on Monday, March 17th. The shares were sold at an average price of $100.52, for a total value of $1,005,200.00. Following the completion of the sale, the chief financial officer now owns 113,860 shares in the company, valued at $11,445,207.20. This represents a 8.07 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 63,109 shares of company stock worth $6,016,046. Company insiders own 1.50% of the company's stock.

Analysts Set New Price Targets

A number of equities research analysts have commented on the company. B. Riley reduced their target price on Lantheus from $127.00 to $122.00 and set a "buy" rating on the stock in a research report on Friday, March 21st. Truist Financial lifted their target price on Lantheus from $120.00 to $127.00 and gave the company a "buy" rating in a report on Thursday, February 27th. Finally, JMP Securities reissued a "market outperform" rating and issued a $112.00 price objective on shares of Lantheus in a research report on Tuesday, January 14th. One research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company's stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $129.43.

Lantheus Price Performance

Shares of LNTH stock traded up $1.26 during mid-day trading on Tuesday, hitting $103.96. The stock had a trading volume of 230,553 shares, compared to its average volume of 861,808. The firm has a market cap of $7.12 billion, a PE ratio of 17.30 and a beta of 0.20. Lantheus Holdings, Inc. has a fifty-two week low of $65.89 and a fifty-two week high of $126.89. The company's 50-day simple moving average is $97.80 and its 200-day simple moving average is $95.08.

Lantheus (NASDAQ:LNTH - Get Free Report) last posted its quarterly earnings results on Thursday, February 27th. The medical equipment provider reported $1.34 EPS for the quarter, missing the consensus estimate of $1.57 by ($0.23). Lantheus had a net margin of 28.57% and a return on equity of 44.29%. The business had revenue of $391.11 million during the quarter, compared to analyst estimates of $376.61 million. On average, analysts expect that Lantheus Holdings, Inc. will post 6.01 EPS for the current year.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.